

	著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	保坂哲也	B 型慢性肝炎、肝硬変： 抗ウイルス療法	福井次矢 高木誠 小室一成	今日の治療 指針	医学書院	東京	2022	540-543	
2)	保坂哲也	B 型慢性肝疾患における 機械学習を用いた肝線維 化予測	中本安成	雑誌肝胆膵 1 月号	アークメ ディア	東京	2022	47-50	○
3)	保坂哲也	臨床疫学からみた肝炎と の闘い（B 型慢性肝炎の 自然史と抗ウイルス療法 の発展）	田中純子	雑誌メディ カル・サイ エンスダイ ジェスト 12 月号	ニューサ イエンス 社	東京	2021	18-21	○
4)	保坂哲也 鈴木義之	B 型慢性肝炎の治療、3 核 酸アナログ	三田英治 平松直樹	必ず役立 つ！肝炎診 療バイブル	メディカ 出版	大阪	2021	126-135	○
5)	佐竹正博	輸血後肝炎の撲滅に向け て	田中純子	Medical Science Digest	ニューサ イエンス 社	東京	2021	10-13	○
6)	瀬戸山博子、島上 哲朗、考藤達哉	日本における肝炎総合対 策	田中純子	Medical Science Digest	ニューサ イエンス 社	東京都 目黒区	2021	No.14, 716-719	○
7)	川口巧、鳥村拓司	第 2 章 栄養療法の基礎 II. 栄養評価 E. 窒素代謝 および窒素平衡	一般社団法人 日本臨床 栄養代謝学 会	日本臨床栄 養代謝学会 JSPEN テキ ストブック	南江堂	東京	2021	164-168	
8)	鳥村拓司	腸内細菌と肝細胞癌	木下芳一、 他 編	専門医のため の消化器 病学	医学書院	東京	2021	444-446	
9)	川口巧、鳥村拓司	代謝異常と中等度飲酒が 脂肪肝患者の肝線維化に およぼす影響	アルコール 医学生物学 研究会 編	アルコール と医学生物 学 Vol. 40	梵天書房	東京	2021	45-46	
10)	相崎英樹	C 型肝炎ウイルスの感染 増殖と病原性発現メカニ ズム、創薬研究者がこれ だけは知っておきたい最 新のウイルス学	技術情報協 会	技術情報協 会	技術情報 協会	東京	2021	3-11	
11)	青柳東代、村松正 道、脇田隆字、相 崎英樹	C 型肝炎のウイルス学と病 態		C 型肝炎患 者の今後の課 題—肝炎、 肝硬変、肝 がん—	消化器内 科	東京	2021	6-13	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Matsugu Y, Ito K, Oshita A, Nobuhara H, <u>Tanaka J</u> , Akita T, Itamoto T	Postoperative oral energy and protein intakes for an enhanced recovery after surgery program incorporating early enteral nutrition for pancreaticoduodenectomy: A retrospective study	Nutrition in Clinical Practice			in press 2022	
2)	Hayes NC, Imamura M, <u>Tanaka J</u> , Chayama K	Road to elimination of HCV: Clinical challenges in HCV management	Liver International			in press 2022	○
3)	Toyoda H, Yasuda S, Shiota S, Kumada T, <u>Tanaka J</u>	Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response	European Journal of Gastroenterology and Hepatology			in press 2022	○
4)	Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <u>Tanaka J</u>	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection	European Radiology			in press 2022	○
5)	Manry J, Bastard P, Gervais A, et al, ( <u>Tanaka J</u> 含む 180 人中 38 番目)	The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies	Research square			in press 2022	
6)	<u>Tanaka J</u> , Kurisu A, Ohara M, Ouoba S, Ohisa M, Sugiyama A, Wang ML, Hiebert L, Kanto T, Akita T	Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study	The Lancet regional health. Western Pacific			in press 2022	○
7)	E B, Ou P, Ouoba S, Hussain Md RA, Ko K, Nagashima S, Sugiyama A, Akita T, <u>Tanaka J</u>	Prevalence and genotype distribution of viral hepatitis B in Cambodia between 1990 and 2020: A Systematic Review and Meta-analysis	Archives of Public Health			in press 2022	○
8)	El-Ekiaby M, <u>Tanaka J</u> , van Drimmelen H, Allain JP, Lelie N	Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?	Journal of Viral Hepatitis	1(1)	26-36	2022	○
9)	Akita S, Fujioka M, Akita T, <u>Tanaka J</u> , Masunaga A, Kawahara T	Effects of hand hygiene using 4% chlorhexidine gluconate or natural soap during hand rubbing followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion in the operating room	Advances in Wound Care	11(1)	1-9	2022	
10)	Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshikawa K, <u>Tanaka J</u> , Muramatsu M, Wakita T, Aizaki H	Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers	Hepatology International	16(1)	68-80	2022	○
11)	Kumada T, Toyoda H, Yasuda S, Ito T, <u>Tanaka J</u>	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	Hepatology Research	52(1)	81-92	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	Ouoba S, Okimoto M, Nagashima S, Kitahara Y, Miwata K, Ko K, E B, Sugiyama A, Takahashi K, Sakaguchi T, Takafuta T, <a href="#">Tanaka J</a>	Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients	Journal of Medical Virology	94(4)	1734-1737	2022	
13)	Imada H, Akita T, Sugiyama A, <a href="#">Tanaka J</a>	Impact of robot-assisted surgery appearance on reduction of annual blood transfusion cases in Japan: application of meta-analysis and NDB open data	Journal of Robotic Surgery	8	1-4	2022	
14)	Nobuhara H, Matsugu Y, <a href="#">Tanaka J</a> , Akita T, Ito K	The preventive effects of perioperative oral care on surgical site infections after pancreatic cancer surgery: a retrospective study	Support Care Cancer	30(4)	3337-3344	2022	
15)	Blach S, Terrault NA, Tacke F, Gamkrelidze I et al, ( <a href="#">Tanaka J</a> 含む 259 人中 6 番目)	Global change in hepatitis C virus prevalence as a cascade of care between 2015 and 2020: a modelling study	The LANCET Gastroenterology and Hepatology	7(5)	396-415	2022	○
16)	Kitagawa H, Kaiki Y, Sugiyama A, Nagashima S, Kurisu A, Nomura T, Omori K, Akita T, Shigemoto N, <a href="#">Tanaka J</a> , Ohge H	Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan	Journal of infection and chemotherapy	28(4)	576-581	2022	
17)	Inoue M, Hirabayashi M, Abe SK, Katanoda K, Sawada N, Lin Y, Ishihara J, Takachi R, Nagata C, Saito E, Goto A, Ueda K, <a href="#">Tanaka J</a> , Hori M, Matsuda T; the Cancer PAF Japan Collaborators	Burden of cancer attributable to modifiable factors in Japan in 2015	Global Health and Medicine	4(1)	26-36	2022	○
18)	Ko K, Takahashi K, Nagashima S, E B, Ouoba S, Hussain MRA, Akita T, Sugiyama A, Sakaguchi T, Tahara H, Ohge H, Ohdan H, Kubo T, Ishikawa N, Takafuta T, Fujii Y, Mimori M, Okada F, Kishita E, Ariyoshi K, Kuwabara M, <a href="#">Tanaka J</a>	Mass screening of SARS-CoV-2 variants using sanger sequencing strategy in Hiroshima, Japan	Scientific Reports	12(1)	2419	2022	
19)	Ko K, Takahashi K, Nagashima S, E B, Ouoba S, Takafuta T, Fujii Y, Mimori M, Okada F, Kishita E, Ariyoshi K, Hussain Md RA, Sugiyama A, Akita T, Kuwabara M, <a href="#">Tanaka J</a>	Exercising the Sanger sequencing strategy for variants screening and full-length genome of SARS-CoV-2 virus during alpha, delta, and omicron outbreaks in Hiroshima	Viruses	14(4)	720	2022	
20)	Sugiyama A, Miwata K, Kitahara Y, Okimoto M, Abe K, Ouoba S, Akita T, Tanimine N, Ohdan H, Kubo T, Nagasawa A, Nakanishi T, Takafuta T, <a href="#">Tanaka J</a>	Long COVID occurrence in COVID-19 survivors	Scientific Reports	12(1)	6039	2022	
21)	Toyoda H, Atsukawa M, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Itobayashi E, Watanabe T, Matsuura K, Shimada N, Abe H, Tsuji K, Itokawa N, Mikami S, Ishikawa T, Oikawa T, Yasuda S, Chuma M, <a href="#">Tanaka J</a>	The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C	Gastro Hep Advances	1(4)	508	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
22)	Kaneyasu Y, Fujiwara H, Nishimura T, Sakurai H, Kazumoto T, Ikushima H, Uno T, Tokumaru S, Harima Y, Gomi H, Toita T, Kita M, Noda S, Takahashi T, Kato S, Hirashima Y, Niibe Y, Nakagawa T, Akita T, <a href="#">Tanaka J</a> , Ohno T, the Working Group of the Gynecological Tumor Committee of the Japanese Radiation Oncology Study Group(JROSG)	A multi-institutional survey of the quality of life after treatment for uterine cervical cancer: A comparison between radical radiotherapy and surgery in Japan	Journal of Radiation Research	62(2)	576-585	2021	
23)	Fujimura K, Sugiyama A, Akita T, Ohisa M, Nagashima S, Katayama K, Maeda R, <a href="#">Tanaka J</a>	Screening for M-proteinemia consisting of monoclonal gammopathy of undetermined significance and multiple myeloma for 30 years among atomic bomb survivors in Hiroshima	International Journal of Hematology	113(4)	538-547	2021	
24)	Ko K, Nagashima S, E B, Ouoba S, Akita T, Sugiyama A, Ohisa M, Sakaguchi T, Tahara H, Ohge H, Ohdan H, Kubo T, Kishita E, Kuwabara M, Takahashi K, <a href="#">Tanaka J</a>	Molecular characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima	PLoS One	16(2)	e0246383	2021	
25)	Toyoda T, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, <a href="#">Tanaka J</a>	Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response	Hepatology Communications	5(7)	1290-1299	2021	○
26)	Kuroda S, Kobayashi T, Tashiro H, Onoe T, Oshita A, Abe T, Kohashi T, Oishi K, Ohmori I, Imaoka Y, <a href="#">Tanaka J</a> , Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology	A multicenter randomized controlled trial comparing administration of antithrombin III after liver resection (HiSCO-05 trial)	Surgery	170(4)		2021	○
27)	Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <a href="#">Tanaka J</a>	Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection	Alimentary Pharmacology and Therapeutics	53(12)		2021	○
28)	Kumada T, Toyoda H, Yasuda S, Sone Y, Ogawa S, Takeshima K, Tada T, Ito T, Sumida Y, <a href="#">Tanaka J</a>	Prediction of hepatocellular carcinoma by liver stiffness measurements using magnetic resonance elastography after eradicating hepatitis C virus	Clinical and translational gastroenterology	12(4)		2021	○
29)	Kumada T, Toyoda H, Yasuda S, Tada T, <a href="#">Tanaka J</a> , Chayama K, Johnson PJ, Irving WL	Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus	Infectious Diseases and Therapy	10(2)		2021	○
30)	Kumada T, Toyoda H, Yasuda S, Tada T, <a href="#">Tanaka J</a>	Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication	European Journal of Gastroenterology and Hepatology	33		2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
31)	Kumada T, Toyoda H, Yasuda S, Tada T, Ito T, <a href="#">Tanaka J</a>	Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis	Journal of Viral Hepatitis	28(9)		2021	○
32)	Sugiyama A, Yamashita M, Ko K, Ohisa M, Akita T, Wakita T, <a href="#">Tanaka J</a>	Epidemiological assessment of interventions to eliminatemother-to-child transmission of hepatitis B virus in Japan	GastroHep	3		2021	○
33)	Maeshige N, Hayashi H, Terashi H, Fujii M, Iwamoto T, Watanabe Yu, Imaoka S, Matsumoto J, Nishikawa M, Takeda N, Mikawa R, Tsuji Y, Higashita R, Ayabe S, Terabe Y, Furukawa M, <a href="#">Tanaka J</a> , Ohura T, Kawabe N	Effect of early rehabilitation on gait, wound and home discharge in lower extremity chronic wound patients: a Japanese multicenter retrospective study	The International Journal of Lower Extremity Wounds		doi:10.1177/15347346211039588	2021	
34)	E B, Ko K, Nagashima S, Ouoba S, Hussain Md RA, Sugiyama A, Akita T, Ohisa M, Chuon C, Mao B, Hossain MS, Ork V, <a href="#">Tanaka J</a>	Dried blood spot-based detection of serological profiles of hepatitis B and C infections and their prevalence in Cambodia	GastroHep	3(4)		2021	○
35)	Toyoda H, Yasuda S, Shiota S, Kumada T, <a href="#">Tanaka J</a>	Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy	Journal of Infection and chemotherapy	27(11)		2021	○
36)	Sugiyama A, Kurisu A, Ouoba S, E B, Ko K, Rakhimov A, Hussain Md RA, Akita T, Harakawa T, Sako T, Koshiyama M, <a href="#">Tanaka J</a>	Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008-2019	Liver International	41(12)		2021	○
37)	Sugimura M, Chimed-Ochir O, Yumiya Y, Ohge H, Shime N, Sakaguchi T, <a href="#">Tanaka J</a> , Takafuta T, Mimori M, Kuwabara M, Asahara T, Kishita E, Kubo T	The Association between Wearing a Mask and COVID-19	International journal of environmental research and public health	18(17)	9131	2021	
38)	Ouoba S, Ouedraogo JCRP, Lingani M, E B, Hussain Md RA, Ko K, Nagashima S, Sugiyama A, Akita T, Tinto H, <a href="#">Tanaka J</a>	Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis	BMC Infectious Disease	21	1126	2021	○
39)	Sugiyama A, Fujii T, Okikawa Y, Sasaki F, Okajima M, Hidaka H, Iwato K, Sato K, Kokubunji A, Takata N, Yamamoto M, <a href="#">Tanaka J</a>	Outcomes of patients who undergo transfusion of fresh frozen plasma: a prospective, observational, multicentre cohort study in Hiroshima, Japan	Journal of Blood Medicine	12(12)	965-973	2021	
40)	Lin Y, Wang C, Kikuchi S, Akita T, <a href="#">Tanaka J</a> , Abe SK, Hirabayashi M, Saito E, Hori M, Katanoda K, Matsuda T, Inoue M, the Cancer PAF Japan Collaborators	Burden of cancer attributable to infection in Japan in 2015	Global Health and Medicine	1(2)	63-69	2021	○
41)	Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, <a href="#">Tanaka J</a>	Serial changes in FIB-4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy	GastroHep	3(1)	37-49	2021	○

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
42)	Ko K, Akita T, Satake M, <u>Tanaka I</u>	Epidemiology of viral hepatitis C: Road to elimination in Japan.	Global Health & Medicine	3(5)	262-269	2021	○
43)	Kumada T, Toyoda H, Yasuda S, Ito T, <u>Tanaka I</u>	Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B	European Journal of Gastroenterology and Hepatology	33(1S Suppl 1)	e898-e904	2021	○
44)	<u>田中純子</u> , 杉山文, 栗栖あけみ	てんかんの疫学調査 JMD Cデータの紹介と NDB 活用の必要性	てんかん診療拠点病院運用の手引き		5-8	2021	
45)	永島慎太郎, 北原良介, 杉山文, 沖本真史, E Bunthen, Ouoba Serge, Ko Ko, 高蓋寿朗, <u>田中純子</u>	感染症指定医療機関の医療従事者における mRNA COVID-19 ワクチン接種に伴う SARS-CoV-2 IgG 抗体定量値と中和能との関係	感染症学会雑誌			2021	
46)	<u>田中純子</u>	総論：日本におけるウイルス性肝炎の疫学と対策	Medical Science Dijest	47(14)	3-5	2021	○
47)	杉山 文, 栗栖あけみ, <u>田中純子</u>	健診受診者集団における NAFLD の疫学	月刊糖尿病	13(7)	20-25	2021	○
48)	<u>田中純子</u> , 秋田智之	C 型肝炎の疫学	消化器内科	3(7)	13-22	2021	○
49)	秋田智之, <u>田中純子</u>	疫学的観点からの COVID-19 流行動態の解析とシミュレーション-広島県データを例として	腎と透析	92(1)	69-79	2021	
50)	Tseng TC, <u>Hosaka T</u> , Liu CJ, Suzuki F, Hong CM, Kumada H, Yang YT, Hsu CY, Su TH, Yang HC, Liu CH, Chen PJ, Chen HH, Kao JH.	Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase.	American Journal of Gastroenterology			in press 2022	○
51)	<u>Hosaka T</u> , Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.	Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir	Hepatology Communications	6	36-49	2022	
52)	Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Muraishi N, Fujiyama S, Sezaki H, <u>Hosaka T</u> , Kobayashi M, Kobayashi M, Suzuki Y, Ikeda K, Kumada H.	Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage	Oncology	100	31-38	2022	
53)	<u>Hosaka T</u> , Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B	Hepatology Research	52	153-164	2022	
54)	Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Iritani S, Fujiyama S, <u>Hosaka T</u> , Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H.	Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment	Oncology	99	611-621	2021	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
55)	Kasuya K, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kajiwara A, Iritani S, Fujiyama S, <u>Hosaka T</u> , Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Eguchi Y, Hashimoto M, Kumada H.	Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib	Internal Medicine	60	345-351	2021	
56)	Suzuki F, <u>Hosaka T</u> , Imaizumi M, Kobayashi M, Ohue C, Suzuki Y, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance	Hepatology Research	51	426-435	2021	
57)	Suzuki F, Sezaki H, <u>Hosaka T</u> , Suzuki Y, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H.	Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir	Hepatology Research	51	503-508	2021	
58)	Fujiyama S, Akuta N, Sezaki H, Kobayashi M, Kawamura Y, <u>Hosaka T</u> , Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study	BMC Gastroenterology	21	189	2021	
59)	Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, <u>Hosaka T</u> , Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H.	Clinicopathological assessment of steatohepatic hepatocellular carcinoma	Clinical Research Hepatology Gastroenterology	6	101799	2021	
60)	Muraishi N, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Iritani S, Fujiyama S, <u>Hosaka T</u> , Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Yasuda I, Kumada H.	Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment	Internal Medicine		PMID: 34511564	2021	
61)	Yamashige D, <u>Hosaka T</u> , Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs	Journal of Gastroenterology	56	1008-1021	2021	
62)	Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, <u>Hosaka T</u> , Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.	PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD	BMC Gastroenterology	21	434	2021	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連	
63)	Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Marino Z, Tateishi R, Minami T, Sangiovanni A, Fornis X, <a href="#">Toyoda H</a> , Brillanti S, Conti F, Degasperis E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Abdelaziz AO, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy CC, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello L, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Camma C, Bruix J, Cabibbo G, Reig M.	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.	Gut			in press	○
64)	Kumada T, <a href="#">Toyoda H</a> , Yasuda S, Miyake N, Tada T, Ito T, Tanaka J	Serial changes in FIB-4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy.	GastroHep			in press	○
65)	Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, <a href="#">Toyoda H</a> , Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH.	Progression rates by age, sex, treatment, and disease activity by AASLD and EASL criteria: data for precision medicine.	Clin Gastroenterol Hepatol			in press	○
66)	Kakegawa T, Sugimoto K, Kuroda H, Suzuki Y, Imajo K, <a href="#">Toyoda H</a>	Diagnostic accuracy of two-dimensional shear wave elastography for liver fibrosis: a multicenter prospective study.	Clin Gastroenterol Hepatol			in press	
67)	Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, <a href="#">Toyoda H</a> , Loomba R, Izumi N	Hepatocellular carcinoma risk assessment for patients with advanced fibrosis after eradication of hepatitis C virus.	Hepatol Commun			in press	○
68)	Imajo K, <a href="#">Toyoda H</a> , Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, Yasui Y, Kurosaki M, Izumi N, Nakajima A, Kumada T	Utility of ultrasound-guided attenuation parameter for the quantification of steatosis with reference to MRI-based proton density fat fraction: a multicenter, prospective study.	Clin Gastroenterol Hepatol			in press	
69)	Kam LY, Huang DQ, Teng MLP, Takahashi H, Tanaka K, Yasuda S, Fung J, Lee TY, Hyogo H, Ono M, Saruwatari J, Oniki K, Yeo YH, Barnett S, Henry L, Li J, Zou B, Cheung RC, Kumada T, Yuen MF, Eguchi Y, <a href="#">Toyoda H</a> , Nguyen MH	Clinical profiles of Asians with NAFLD: a systematic review and meta-analysis.	Dig Dis			in press	



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
70)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y.	Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis.	Eur J Gastroenterol Hepatol			in press	
71)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M.	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to 7 criteria – multicenter analysis.	Hepatol Res			in press	
72)	Atsukawa M, Tsubota A, Kondo C, <u>Toyoda H</u> , Nakamura M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K, KTK49 Liver Study Group	Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis	Hepatol Res			in press	○
73)	Kawamura N, Imajo K, Kalutkiewicz KJ, Nagai K, Iwaki M, Kobayashi T, Nogami A, Honda Y, Kessoku T, Ogawa Y, Higurashi T, Hosono K, Takahashi H, Yoneda M, Saito S, Aishima S, <u>Toyoda H</u> , Hayashi H, Sumida Y, Ehman RL, Nakajima A.	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.	Hepatology			in press	
74)	Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study	Clin Gastroenterol Hepatol			in press	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
75)	Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, <u>Toyoda H</u> , Ogawa C, Kudo M, JSUM AI investigators.	Development of artificial intelligence (AI) for the ultrasonographic diagnosis of liver tumor and comparison of diagnostic accuracy with AI versus human experts.	J Gastroenterol			in press	
76)	Johnson P, Pinato DJ, Kalyuzhnyy A, <u>Toyoda H</u>	Breaking the Child-Pugh dogma in hepatocellular carcinoma	J Clin Oncol			in press	
77)	Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kumada T.	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a landmark analysis.	Hepato Res			in press	
78)	Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, <u>Toyoda H</u> , Esquivel CO, Bonham CA, Nguyen MH, Huang DQ.	Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies	Hepato Commun			in press	
79)	<u>Toyoda H</u> , Yasuda S, Shiota S, Kumada T, Tanaka J.	Adherence to regular surveillance visits for HCC in patients with chronic hepatitis C virus infection who achieved sustained virologic response.	Eur J Gastroenterol Hepato			in press	○
80)	<u>Toyoda H</u> , Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, Tanaka J.	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection.	Eur Radiol			in press	○
81)	Hiraoka A, Kumada T, Kariyama K, <u>Toyoda H</u> , Yasuda S, Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Ishikawa T, Tada T, Takaguchi K, Itobayashi E, Shimada N, Tanaka T, Tsutsui A, Nagano T, Imai M, Nakamura S, Nouse K, Shibata H.	Simple scoring system for predicting TACE unsuitable among intermediate stage hepatocellular carcinoma patients in multiple systemic treatment era.	Oncology	100	65-73	2022	
82)	Tada T, Kumada T, <u>Toyoda H</u> , Nakamura S, Endo Y, Kaneoka Y, Hiraoka A, Joko K, Hirooka M, Hiasa Y	A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma	Clin Radiol	77	114-120	2022	
83)	Kumada T, <u>Toyoda H</u> , Yasuda S, Ito T, Tanaka J.	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	Hepato Res	52	81-92	2022	○
84)	Shiha G, Soliman R, Mikhail NNH, Alswat K, Abdo AA, Sanai FM, Derbala MFM, Ormeci N, Dalekos GN, Al-Busafi SA, Hamoudi W, Sharara AI, Zaky S, El-Raey F, Mabrouk MS, Marzouk SY, <u>Toyoda H</u>	Development and multicenter validation of FIB-6; a novel, machine-learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in CHC patients.	Hepato Res	52	165-175	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
85)	<u>Toyoda H</u> , Yasuda S, Shiota S, Kumada T.	Long-term persistence of hepatocarcinogenic potential of a non-hypervascular hypointense nodule on EOB-MRI after the eradication of hepatitis C virus.	Hepato Res	52	128-132	2022	○
86)	Yamamoto T, Ito T, Hase, T, Ishigami, M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, <u>Toyoda H</u> , Abe T, Kawashima H, Hashimoto N, Fujishiro M	Immune-related liver injury is a poor prognostic factor in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.	Cancer Invest	40	189-198	2022	
87)	Tada T, <u>Toyoda H</u> , Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J.	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.	J Viral Hepat	28	538-547	2021	○
88)	Itokawa N, Atsukawa M, Tsubota A, Shimada N, <u>Toyoda H</u> , Takaguchi K, Hiraoka A, Senoh T, Koeda M, Yoshida Y, Okubo T, Arai T, Hayama K, Nakagawa-Iwashita A, Kondo C, Iwakiri K.	Factors associated with hepatitis B surface antigen kinetics and responses in pegylated interferon alpha-2a monotherapy for patients with chronic hepatitis B.	Intern Med	60	507-516	2021	○
89)	Yoshida K, Desbiolles A, Feldman SF, Ahn SH, Alidjinou EK, Atsukawa M, Bocket L, Brunetto MR, Buti M, Carey I, Caviglia GP, Chen EQ, Chuaypen N, Cornberg M, Enomoto M, Honda M, zu Siederdissen CH, Ishigami M, Janssen HLA, Maasoumy B, Matsui T, Matsumoto A, Nishiguchi S, Riveiro-Barciela M, Takaki A, Tangkijvanich P, <u>Toyoda H</u> , van Campenhout MJH, Wang B, Wei L, Yang HI, Yano Y, Yatsushashi H, Yuen MF, Tanaka E, Lemoine M, Tanaka Y, Shimakawa Y.	Assay for hepatitis B core-related antigen identify patients with high viral load: systematic review and meta-analysis of individual participant data.	Clin Gastroenterol Hepatol	19	46-60	2021	○
90)	Saito A, <u>Toyoda H</u> , Kobayashi M, Koiwa Y, Fujii H, Fujita K, Maeda A, Kaneoka Y, Hazama S, Nagano H, Mirza A, Graf HP, Cosatto E, Murakami Y, Kuroda M.	Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning.	Mod Pathol	34	417-425	2021	
91)	Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y.	Platelet-lympgocyte ratio predicts survival in patioents with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis.	Eur J Gastroenterol Hepatol	32	261-268	2021	
92)	Kumada T, <u>Toyoda H</u> , Tada T, Yasuda S, Miyake N, Tanaka J.	Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.	Eur J Gastroenterol Hepatol	32	255-260	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
93)	Johnson PJ, Berhane S, Walker AJ, Gordon FH, Ryder SD, McPherson S, Sreedharan A, Ustianowski AA, Agarwal K, Mutimer D, Kumada T, <u>Toyoda H</u> , Irving WL, HCV Research UK.	Impact of direct acting antiviral agents on liver function in patients with chronic hepatitis C virus infection.	J Viral Hepat	28	168-176	2021	○
94)	Hughes DM, Berhane S, de Groot CAE, <u>Toyoda H</u> , Tada T, Kumada T, Satomura S, Nishida N, Kudo M, Kimura T, Osaki Y, Kokamunage-Dona R, Salvador RA, Bird T, Garcia-Finana M, Johnson P.	Serum levels of alpha fetoprotein increased more than 10 years before detection of hepatocellular carcinoma.	Clin Gastroenterol Hepatol	19	162-170	2021	○
95)	Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, Arai T, Fukunishi S, Ogawa E, Hsu YC, Maeda M, Dang H, Tseng CH, Takahashi H, Jun DW, Watanabe T, Chuma M, Nozaki A, Kawada N, Cheung R, Enomoto M, Takaguchi K, <u>Toyoda H</u> .	Outcomes of sequential therapy with tenofovir alafenamide following long-term entecavir.	Am J Gastroenterol	116	1264-1273	2021	○
96)	Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouse K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y	Impact of early lenvatinib administration on survival in patients with intermediate-stage hepatocellular carcinoma: a multicenter, inverse probability weighting analysis	Oncology	99	518-527	2021	
97)	<u>Toyoda H</u> , Leong J, Landis C, Atsukawa M, Watanabe T, Huang DQ, Liu J, Quek SXZ, Ishikawa T, Arai T, Yokohama K, Chuma M, Takaguchi K, Uojima H, Senoo T, Dang H, Maeda M, Hoang J, Le RH, Yasuda S, Thin KN, Tran S, Chien N, Henry L, Asai A, Fukunishi S, Cheung R, Lim SG, Trinh HN, Nguyen MH.	Treatment and renal outcomes up to 96 weeks after tenofovir alafenamide switch from tenofovir disoproxil fumarate in routine practice.	Hepatology	74	656-666	2021	○
98)	<u>Toyoda H</u> , Yasuda S, Shiota S	Editorial: is there a “precursor” HCC lesion and can it be detected by hepatobiliary contrast-enhanced magnetic resonance imaging? – authors’ reply.	Aliment Pharmacol Ther	54	204-205	2021	
99)	<u>Toyoda H</u> , Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, Tanaka J.	Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI is a strong predictor of HCC development after SVR in patients with HCV infection.	Aliment Pharmacol Ther	53	1309-1316	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
100)	Chuma M, Uojima H, Hiraoka A, Kobayashi S, <u>Toyoda H</u> , Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouse K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S.	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis.	Hepatol Res	51	201-215	2021	
101)	Nouse K, Furubayashi Y, Kariyama K, Wakuta A, Miyake N, Inoue K, Nagai Y, Murakami S, Adachi T, Oyama A, Wada N, Takeuchi Y, Sakata M, Yasunaka T, Onishi H, Shiraha H, Takaki A, Shiota S, Yasuda S, <u>Toyoda H</u> , Kawanaka M, Kumada T, Okada H.	Abnormal fucosylation of alpha-fetoprotein in patients with non-alcoholic steatohepatitis.	Hepatol Res	51	548-553	2021	
102)	Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, <u>Toyoda H</u> , Ogawa C, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M	Therapeutic efficacy of lenvatinib as third line treatment following regorafenib for unresectable hepatocellular carcinoma progression	Hepatol Res	51	880-889	2021	
103)	Casadei-Gardini A, Scartozzi M. Tada T, Yoo C, Shimose S, Masi G, Lonardi S, Frassinetti LG, Nicola S, Piscaglia F, Kumada T, Kim HD, Koga H, Vivaldi C, Solda C, Hiraoka A, Bang Y, Atsukawa M, Torimura T, Tsuji K, Itobayashi E, <u>Toyoda H</u> , Fukunishi S, Rimassa L, Rimini M, Cascinu S, Cucchetti A.	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis.	Liver Int	41	1389-1397	2021	
104)	Rapposelli IG, Tada T, Shimose S, Burgio V, Kumada T, Iwamoto H, Hiraoka A, Niizeki T, Atsukawa M, Koga H, Hirooka M, Torimura T, Iavarone M, Tortora, R, Campani C, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo, G, Foschi FG, Silletta M, Tsuji K, Ishikawa T, Takaguchi, K, Kariyama, K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawaka K, Tani J, Nakamura S, Nouse K, Tsutsui A, Nagano T, Tanaka T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Rimini M, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A.	Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib	Liver Int	41	2997-3008	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
105)	Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, <u>Toyoda H</u> , Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M.	Clinical importance of muscle volume in lenvatinib for hepatocellular carcinoma: analysis adjusted with inverse probability weighting.	J Gastroenterol Hepatol	36	1812-1819	2021	
106)	<u>Toyoda H</u> , Kikuchi K, Tsuruta Y, Hiraoka A, Tsuji K, Tanaka J.	Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis.	Nephrol Dial Transpl	36	1097-1103	2021	○
107)	Kumada T, <u>Toyoda H</u> , Yasuda S, Tada T, Tanaka J	Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication	Eur J Gastroenterol Hepatol	33	e513-e521	2021	○
108)	Kumada T, <u>Toyoda H</u> , Yasuda S, Miyake N, Ito T, Tanaka J.	Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.	J Viral Hepat	28	508-516	2021	○
109)	Kumada T, <u>Toyoda H</u> , Yasuda S, Tada T, Ito T, Tanaka J.	Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis	J Viral Hepat	28	1293-1303	2021	○
110)	<u>Toyoda H</u> , Yasuda S, Shiota S, Kumada T, Tanaka J	Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy.	J Infect Chemother	27	1674-1675	2021	○
111)	Yamada N, Matsushima-Nishiwaki R, Kobayashi K, Takahata S, <u>Toyoda H</u> , Kumada T, Kozawa O.	Cellular function of small heat shock proteins (HSPB) in hepatocellular carcinoma.	Cuur Mol Med	21	872-887	2021	
112)	<u>Toyoda H</u> , Hiraoka A, Olivares J, Al-Jarrah T, Devlin P, Kaneoka Y, Maeda A, Yopp AC, Parikh ND, Singal AG.	Outcome of hepatocellular carcinoma detected during surveillance: comparing USA and Japan.	Clin Gastroenterol Hepatol	19	2379-2388	2021	○
113)	Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobaru M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, <u>Toyoda H</u> , Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K.	A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C	PLoS ONE	16	e0257166	2021	○

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
114) Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung M, <u>Toyoda H</u> , Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HL, Nguyen MH.	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.	Hepatol Int	15	71-81	2021	○
115) Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M, Maeda M, Thin KN, Tanaka K, Takahashi Y, Itoh Y, Oniki K, Seko Y, Saruwatari J, Kawanaka M, Atsukawa M, Hyogo H, Ono M, Ogawa E, Barnett SD, Stave CD, Cheung RC, Fujishiro M, Eguchi Y, <u>Toyoda H</u> , Nguyen MH.	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040.	Hepatol Int	15	366-379	2021	○
116) Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, <u>Toyoda H</u> , Yasuda S, Nguyen MH, Yu ML	Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma.	Hepatol Int	15	946-956	2021	
117) Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H, Yasuda S, <u>Toyoda H</u> , Yokota K, Hase T, Maeda O, Kato M, Hashimoto N, Hibi H, Ebata T, Kodera Y, Sone M, Ando Y, Akiyama M, Shimoyama Y, Fujishiro M	Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.	Hepatol Int	15	1278-1287	2021	
118) Schotten C, Ostertag B, Sowa JP, Manka P, Bechmann LP, Hilgard G, Marquardt C, Wichert M, <u>Toyoda H</u> , Lange CM, Canbay A, Johnson P, Wedemeyer H, Best J	GALAD Score detects early-stage hepatocellular carcinoma in a European cohort of chronic hepatitis B and C patients.	Pharmaceuticals	14	735	2021	
119) Kumada T, <u>Toyoda H</u> , Yasuda S, Sone Y, Ogawa S, Takeshima K, Tada T, Ito T, Sumida Y, Tanaka J	Prediction of hepatocellular carcinoma by liver stiffness measurements using magnetic resonance elastography after eradicating hepatitis C virus.	Clin Transl Gastroenterol	12	e00337	2021	○
120) Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience	Cancer Rep	11	e1464	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
121)	Tada T, Kumada T, Hiraoka A, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouse K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y.	Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib: an analysis using time-dependent ROC	Sci Rep	11	14474	2021	
122)	Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, <u>Toyoda H</u> , Aoki T, Tanaka T, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M	Effdicacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study	Sci Rep	11	16663	2021	
123)	Tada T, Kumada T, Okushin H, Tani J, Takaguchi K, Tsutsui A, <u>Toyoda H</u> , Yasuda S, Dohmen K, Hiraoka A, Michitaka K, Nouse K, Kariyama K, Kim SR, Kim SK, Fujioka S, Mikami S, Watanabe Y, Tamai T, Atsukawa M, Itokawa N, Tanaka H, Tsuji K, Ishikawa T, Imai M, Itobayashi E, Shibata H, Shimada N.	Real-world virological efficacy and safety of ledipasvir and sofosbuvir in patients with chronic hepatitis C virus genotype 2 infection in Japan.	Infect Dis Ther	10	269-280	2021	○
124)	Hiraoka A, Kumada T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, <u>Toyoda H</u> , Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M.	What can be done to solve the unmet clinical need of hepatocellular carcinoma patients following lenvatinib failure?	Liver Cancer	10	115-125	2021	
125)	Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, <u>Toyoda H</u> , Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T.	Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update.	Liver Cancer	10	181-223	2021	
126)	Kumada T, <u>Toyoda H</u> , Yasuda S, Tada T, Tanaka J, Chayama K, Johnson PJ, Irving WL	Comparison of the prognosis of decompensated cirrhosis in patients with and without eradication of hepatitis C virus	Infect Dis Ther	10	1001-1013	2021	○



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
127)	Rapposelli IG, Shimose S, Kumada T, Okamura S, Hiraoka A, Di Costanzo GG, Marra F, Tamburini E, Forgione A, Foschi FG, Silletta M, Lonardi S, Masi G, Scartozzi M, Nakano M, Shibata H, Kawata K, Pellino A, Vivaldi C, Lai E, Takata A, Tajiri K, <u>Toyoda H</u> , Tortora R, Campani C, Viola MG, Piscaglia F, Conti F, Fulgenzi CAM, Frassinetti GL, Rizzato MD, Salani F, Astara G, Torimura T, Atsukawa M, Tada T, Burgio V, Rimini M, Cascinu S, Casadei-Gardini A	Identification of LEnvatinib Prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.	ESMO Open	6	100190	2021	
128)	Rimini M, Kudo M, Tada T, Shimose S, Kang W, Suda G, Jefremow A, Burgio V, Iavarone M, Tortora R, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Kumada T, Iwamoto H, Aoki T, Goh MJ, Sakamoto N, Siebler J, Hiraoka A, Niizeki T, Ueshima K, Sho T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouse K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Cucchetti A, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib	ESMO Open	6	100330	2021	
129)	<u>Toyoda H</u> , Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J.	Characteristics and prognosis of de novo hepatocellular carcinoma after sustained virologic response.	Hepatol Commun	5	1290-1299	2021	○
130)	<u>Toyoda H</u> , Yasuda S, Shiota S, Chatani S, Tsukii R, Kitagawa H, Fukushima T, Urasaki S, Kumada T	Safety, feasibility, and comfort of hepatic angiography and transarterial intervention with radial access for hepatocellular carcinoma.	JGH Open	5	1041-1046	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
131)	Munoz-Martinez S, Sapena V, Forner A, Nault JC, Sapisochin G, Rimasa L, Sangro B, Bruix J, Sanduzzi-Zamparelli M, Holowko W, El Kassas M, Mocan T, Bouattour M, Merle P, Hoogwater FJH, Alqahatni SA, Reeves HL, Pinato DJ, Giorgakis E, Meyer T, Villadsen GE, Wege H, Salati M, Minguez B, Di Costanzo GG, Roderburg C, Tacke F, Varela M, Galle PR, Alvares-da-Silva MR, Trojan J, Bridgewater J, Cabibbo G, Toso C, Lachenmayer A, Casadei-Gardini A, <u>Toyoda H</u> , Ludde T, Villani R, Pena AMM, Leal CRG, Ronzoni M, Delgado M, Perello C, Pascual S, Lledo JL, Argemi J, Basu B, da Fonseca L, Acevedo J, Siebenhuener AR, Braconi C, Meyers BM, Granito A, Sala M, Lope CR, Blaise L, Romero-Gomez M, Pinero F, Gomez D, Mello V, Pinheiro Alves RC, Franca A, Branco F, Brandi G, Pereira G, Coll S, Guarino M, Benitez C, Anders MM, Bandi JC, Vergara M, Calvo M, Peck-Radosavljevic M, Garcia-Juarez I, Cardinale V, Lozano M, Gambato M, Okolicsanyi S, Arraez DM, Elvevi A, Munoz AE, Lue A, Iavarone M, Reig M.	Assessment of the impact of COVID-19 pandemic on liver cancer management (CERO-19).	JHEP Rep	3	100260	2021	
132)	<u>Miyasaka A</u> , Yoshida Y, Murakami A, Hoshino T, Sawara K, Numao H, Takikawa Y.	Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection.	Health Sci Rep.	5	e458	2022	○
133)	<u>Miyasaka A</u> , Sato S, Masuda T, Takikawa Y.	A 55-Year-Old Japanese Man with Multiple Sclerosis Diagnosed with Disseminated Tuberculosis Identified by Liver Function Abnormalities: A Case Report.	Am J Case Rep.	22	e931369	2021	
134)	<u>Miyasaka A</u> , Yoshida Y, Suzuki A, Takikawa Y.	Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response.	Qual Life Res.	30	3501-3509	2021	○
135)	<u>Miyasaka A</u> , Yoshida Y, Suzuki A, Sawara K, Takikawa Y.	A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination.	International Journal of General Medicine.	14	9845-9854	2021	○
136)	Ko K, Akita T, <u>Satake M</u> , Tanaka J.	Epidemiology of viral hepatitis C: Road to elimination in Japan	Glob Health Med	3(5)	262-9	2021	○
137)	Matsuno T, Matsuura H, Fujii S, Tanaka A, <u>Satake M</u> , Kinoshita T, Tomita A, Matsui Y, Sugiura Y, Miura Y.	Prolonged incubation period of hepatitis B in a recipient of a nucleic acid amplification test-negative hepatitis B virus window donation.	Transfusion	61(9)	2782-7	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
138)	Sakata H, Matsubayashi K, Iida J, Nakauchi K, Kishimoto S, Sato S, Ikuta K, <u>Satake M</u> , Kino S.	Trends in hepatitis E virus infection: Analyses of the long-term screening of blood donors in Hokkaido, Japan, 2005-2019.	Transfusion	61(12)	3390-401	2021	
139)	<u>Shimakami T</u> , Kaneko S.	Use of information and communication technology in the support of viral hepatitis patients in Japan.	Glob Health Med.	3(5)	314-320	2021	○
140)	Kawaguchi K, Sakai Y, Terashima T, Shimode T, Seki A, Orita N, Takeshita Y, <u>Shimakami T</u> , Takatori H, Arai K, Kitamura K, Yamashita T, Yamashita T, Takamura M, Mizukoshi E, Takamura T, Honda M, Wada T, Kaneko S.	Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease.	Medicine (Baltimore)	100(31)	e26835	2021	
141)	Dultz G, Srikakulam SK, Konetschnik M, <u>Shimakami T</u> , Doncheva NT, Dietz J, Sarrazin C, Biondi RM, Zeuzem S, Tampé R, Kalinina OV, Welsch C.	Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability.	J Biol Chem.	297(3)	101031	2021	
142)	Shirasaki T, Murai K, Honda M, Okada H, Innami Y, Yamada A, <u>Shimakami T</u> , Kawaguchi K, Yamashita T, Sakai Y, Kaneko S.	Establishment of liver tumor cell lines from atherogenic and high fat diet fed hepatitis C virus transgenic mice.	Sci Rep.	11(1)	13021	2021	
143)	Chen H, Nio K, Yamashita T, Okada H, Li R, Suda T, Li Y, Doan PTB, Seki A, Nakagawa H, Toyama T, Terashima T, Iida N, <u>Shimakami T</u> , Takatori H, Kawaguchi K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S.	BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma.	Mol Oncol.	15(8)	2203-2218	2021	
144)	Yamashita T, Koshikawa N, <u>Shimakami T</u> , Terashima T, Nakagawa M, Nio K, Horii R, Iida N, Kawaguchi K, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kitao A, Kobayashi S, Takahara S, Imai Y, Yoshimura K, Murayama T, Nakamoto Y, Yoshida E, Yoshimura T, Seiki M, Kaneko S.	Serum Laminin $\gamma$ 2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma.	Hepatology	74(2)	760-775	2021	○
145)	Ogawa Y, Nakahara T, Ono M, Kawaguchi T, Isoda H, Hiramatsu A, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Yamauchi M, Tsuge M, Munekage K, Ochi T, Hayes CN, Imamura M, Aikata H, Takahashi H, <u>Torimura T</u> , Chayama K	Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease	Journal of Gastroenterology and Hepatology			in press 2021	
146)	Shirono T, Koga H, Niizeki T, Nagamatsu H, Iwamoto H, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Ogo E, <u>Torimura T</u>	Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study	Cancer Reports			in press 2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
147)	Kamachi N, Nakano M, Okamura S, Niizeki T, Iwamoto H, Shimose S, Shirono T, Noda Y, Kuromatsu R, Koga H, <a href="#">Torimura T</a>	Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound	Cancer Reports			in press 2021	○
148)	Iwamoto H, Itano S, Itano O, Ishii M, Niizeki T, Shirono T, Shimose S, Suzuki H, Kajiwara A, Yamaguchi T, Koga H, <a href="#">Torimura T</a>	Feasibility and safety of a novel indwelling catheter system via the femoral artery for intermittent transarterial therapy for treating malignant liver tumors	Japanese Journal of Radiology			in press 2021	
149)	Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Kajiwara A, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Koga H, <a href="#">Torimura T</a>	Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival	Oncology	99: 12	756-765	2021	○
150)	Yoshimura T, Mitsuyama K, Sakemi R, Takedatsu H, Yoshioka S, Kuwaki K, Mori A, Fukunaga S, Araki Y, Morita M, Tsuruta K, Yamasaki H, <a href="#">Torimura T</a>	Evaluation of Serum Luecine-rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease	Mediators of Inflammation	8825374:	1-10	2021	
151)	Mori A, Mitsuyama K, Sakemi R, Yoshioka S, Fukunaga S, Kuwaki K, Yamauchi R, Araki T, Yoshimura T, Yamasaki H, Tsuruta K, Morita T, Yamasaki S, Tsuruta O, <a href="#">Torimura T</a>	Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease	The Kurume Medical Journal	66: 4	209-215	2021	
152)	Yamamura S, Kawaguchi T, Nakano D, Tomiyasu Y, Yoshinaga S, Doi Y, Takahashi H, Anzai K, Eguchi Y, <a href="#">Torimura T</a>	Prevalence and Independent Factors for Fatty Liver and Significant Hepatic Fibrosis Using B-Mode Ultrasound Imaging and Two Dimensional-Shear Wave Elastography in Health Check-up Examinees	The Kurume Medical Journal	66: 4	225-237	2021	
153)	Rapposelli IG, Shimose S, Kumada T, Okamura S, Hiraoka A, Costanzo GDi, Marra F, Tamburini E, Forgione A, Foschi FG, Silletta M, Lonardi S, Masi G, Scartozzi M, Nakano M, Shibata H, Kawata K, Pellino A, Vivaldi C, Lai E, Takata A, Tajiri K, Toyoda H, Tortora R, Campani C, Viola MG, Piscaglia F, Conti F, Fulgenzi CAM, Frassinetti GL, Rizzato MD, Salani F, Astaro G, <a href="#">Torimura T</a> , Atsukawa M, Tada T, Burgio V, Rimini M, Cascinu S, Casadei-Gardini A	Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma	ESMO Open	6: 4	100190	2021	
154)	Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, <a href="#">Torimura T</a> , Kurume Liver Cancer Study Group of Japan	Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma	ESMO Open	6: 1	100020	2021	○
155)	Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shigeo S, Shirono T, Noda Y, Kamachi N, Koga H, <a href="#">Torimura T</a>	Evaluating the effect of intrahepatic lesion status on the prognosis of advanced hepatocellular carcinoma patients with extrahepatic metastasis: A prospective multicenter cohort study	Journal of Translational Science	6 :	1-7	2021	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
156)	Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, <u>Torimura T</u> , Yoshizawa K, Takaki A, Kang JH, Suzuki Y, Nakamoto N, Inui A, Tanaka A, Takikawa H	Differences in autoimmune hepatitis based on inflammation localization	Medical Molecular Morphology	54: 1	8-13	2021	
157)	Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, George J, <u>Torimura T</u>	MAFLD Better Predicts the Progression of Atherosclerotic Cardiovascular Risk than NAFLD: Generalized Estimating Equation Approach	Hepatology Research	51; 11	1115-1128	2021	
158)	Hashida R, Matsuse H, Kawaguchi T, Yoshio S, Bekki M, Iwanaga S, Sugimoto T, Hara K, Koya S, Hirota K, Nakano D, Tsutsumi T, Kanto T, <u>Torimura T</u> , Shiba N	Effects of A Low-Intensity Resistance Exercise Program on Serum miR-630, miR-5703, and Fractalkine/CX3CL1 Expressions in Subjects with No Exercise Habits: A Preliminary Study	Hepatology Research	51:7	823-833	2021	
159)	Kawaguchi T, Honda A, Sugiyama Y, Nakano D, Tsutsumi T, Tahara N, <u>Torimura T</u> , Fukumoto Y	Association between the Albumin-Bilirubin (ALBI) Score and Severity of Portoplummonary Hypertension (PoPH): A Data-mining Analysis	Hepatology Research	51: 12	1207-1218	2021	
160)	Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, <u>Torimura T</u> , Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: a multi-institutional matched case-control study	Hepatology Research	51: 12	1229-1241	2021	
161)	Toshihiro Tanaka, Hideki Iwamoto, Mitsuteru Fujihara, Hideyuki Nishiofuku, Tetsuya Masada, Hiroyuki Suzuki, Hironori Koga, <u>Takuji Torimura</u> , Kimihiko Kichikawa	Efficacy of a Glass Membrane Emulsification Device to Form Mixture of Cisplatin Powder with Lipiodol on Transarterial Therapy for Hepatocellular Carcinoma	CardioVascular and Interventional Radiology	44: 5	766-773	2021	
162)	Casadei-Gardini A, Scartozzi M, Tada T, Yoo C, Shimose S, Masi G, Lonardi S, Frassinetti GL, Nicola S, Piscaglia F, Kumada T, Hyung-Don K, Koga H, Vivaldi C, Soldà C, Hiraoka A, Bang Y, Atsukawa M, <u>Torimura T</u> , Tsuj K, Itobayashi E, Toyoda H, Fukunishi S, Rimassa L, Rimini M, Cascinu S, Cucchetti A	Lenvatinib versus Sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis	Liver International	41: 6	1389-1397	2021	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
163) Rapposelli IG, Tada T, Shimose S, Burgio V, Kumada T, Iwamoto H, Hiraoka A, Niizeki T, Atsukawa M, Koga H, Hirooka M, <u>Torimura T</u> , Iavarone M, Tortora R, Campani C, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouse K, Tsutsui A, Nagano T, Tanaka T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Rimini M, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A	Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib	Liver International	41: 12	2997-3008	2021	
164) Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M, Kawaguchi T, <u>Torimura T</u> , Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, Wada K, Kobayash N, Sumida Y, Saito S, Nakajima A	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease	Journal of Gastroenterology and Hepatology	36: 8	2275-2284	2021	
165) Hashida R, Takano Y, Matsuse H, Kudo M, Bekki M, Omoto M, Nago T, Kawaguchi T, <u>Torimura T</u> , Shiba N.	Electrical Stimulation of the Antagonist Muscle during Cycling Exercise Interval Training Improves Oxygen Uptake and Muscle Strength.	Journal of Strength and Conditioning Research	35: 1	111-117	2021	
166) <u>Torimura T</u> , Iwamoto H	Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects	Clinical and Molecular Hepatology	27: 2	236-245	2021	○
167) Fukunaga S, Nakano D, Kawaguchi T, Eslam M, Ouchi A, Nagata T, Kuroki H, Kawata H, Abe H, Nouno R, Kawaguchi K, George J, Mitsuyama K, <u>Torimura T</u>	Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study	International journal of molecular sciences	22: 11	5462	2021	
168) Araki T, Mitsuyama K, Yamasaki H, Morita M, Tsuruta K, Mori A, Yoshimura T, Fukunaga S, Kuwaki K, Yoshioka S, Takedatsu H, Kakuma T, Akiba J, <u>Torimura T</u>	Therapeutic Potential of a Self-Assembling Peptide Hydrogel to Treat Colonic Injuries Associated with Inflammatory Bowel Disease	Journal of Crohn's and Colitis	15: 9	1517-1527	2021	
169) Toshihiro Kawaguchi, Tatsuya Ide, Keisuke Amano, Teruko Arinaga-Hino, Reichihiro Kuwahara, Tomoya Sano, Shirachi Miki, Naofumi Ono, <u>Takuji Torimura</u>	Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication	Molecular and Clinical Oncology	15: 4	215	2021	○
170) Kamachi N, Shimose S, Hirota K, Koya S, Iwamoto H, Niizeki T, Shirono T, Nakano M, Hashida R, Kawaguchi T, Matuse H, Noguchi K, Koga H, <u>Torimura T</u>	Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma	Molecular and Clinical Oncology	14: 4	79	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
171)	Fukahori M, Kato K, Taniguchi H, Ohtomo R, Takahashi N, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Yamada Y, Shimada Y, Ito Y, Itami J, Hokamura N, Igaki H, Tachimori Y, Miwa K, <u>Torimura T</u> and Boku N	Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations	Molecular and Clinical Oncology	14 : 2	41	2021	
172)	Suzuki H, Iwamoto H, Nakano M, Nakamura T, Masuda A, Sakae T, Tanaka T, Nakano D, Kuromatsu R, Niizeki T, Okamura S, Shimose S, Shirono T, Noda Y, Kamachi N, Yano H, Kawaguchi A, Koga H, <u>Torimura T</u>	Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments	Translational Oncology	14 : 11	101201	2021	
173)	Sano T, Amano K, Ide T, Kawaguchi T, Kuwahara R, Arinaga-Hino T, Koga H, Kuromatsu R, <u>Torimura T</u>	Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alafenamide for chronic hepatitis B	Biomedical Reports	14: 1	12	2021	
174)	Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwarra M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, <u>Torimura T</u>	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma	Cancers	13: 4	646	2021	○
175)	Zaizen Y, Nakano M, Fukumori K, Yano Y, Takaki K, Niizeki T, Kuwaki K, Fukahori M, Sakae T, Yoshimura S, Nakazaki M, Kuromatsu R, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, <u>Torimura T</u>	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis	Cancers	13: 21	5282	2021	○
176)	Tsuchihashi J, Koya S, Hirota K, Koga N, Narao H, Tomita M, Kawaguchi T, Hashida R, Nakano D, Tsutsumi T, Yoshio S, Matsuse H, Sanada T, Notsumata K, <u>Torimura T</u>	Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma	Cancers	13: 2	194	2021	
177)	Niizeki T, Iwamoto H, Shirono T, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Hiroyuki S, Sakai M, Kuromatsu R, Koga H and <u>Torimura T</u>	Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion	Cancers	13: 17	4450	2021	○
178)	Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwarra A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, <u>Torimura T</u> and on behalf of The Kurume Liver Cancer Study Group of Japan	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice	Cancers	13: 11	2786	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
179)	Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, <u>Torimura T</u>	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study	Cancers	13: 1	160	2021	○
180)	Hashida R, Dan Nakano, Sakura Yamamura, Takumi Kawaguchi, Tsubasa Tsutsumi, Hiroo Matsuse, Hirokazu Takahashi, ,Zobair M. Younossi and <u>Takuji Torimura</u>	Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis	Life (Basel)	11 : 8	799	2021	
181)	Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, <u>Torimura T</u> , Anzai K, Eguchi Y, Takahashi H	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees	Diagnostics	11: 1	132	2021	
182)	Fukahori M, Miwa K, Murotani K, Naito Y, Ushijima T, Sakaue T, Tanaka T, Nagasu S, Suga H, Kakuma T, Okabe Y, <u>Torimura T</u>	A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer	Medicine	100: 20	26052	2021	
183)	Shirono T, Niizeki T, Iwamoto H, Shimose S, Suzuki H, Kawaguchi T, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatu R, Koga H, <u>Torimura T</u>	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis	Journal of Clinical Medicine	10: 5	987	2021	
184)	Shimose S, Hiraoka A, Nakano M, Iwamoto H, Tanaka M, Tanaka T, Noguchi K, Aino H, Ogata K, Kajiwara M, Itano S, Yokokura Y, Yamaguchi T, Kawano H, Matsukuma N, Suga H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Kawaguchi T, Koga H, <u>Torimura T</u>	First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study	Cancer Medicine	10: 23	8530-8541	2021	○
185)	Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, <u>Hino K</u> , Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y.	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma	Liver Cancer			in press 2022	
186)	Nishina S, <u>Hino K</u> .	CD26/DPP4 as a therapeutic target in nonalcoholic steatohepatitis associated hepatocellular carcinoma	Cancers	14	454	2022	
187)	<u>Hino K</u> , Yanatori I, Hara Y, Nishina S.	Iron and liver cancer: an inseparable connection	FEBS J		doi: 10.1111 /febs.16208.	2021	
188)	Nishikawa H, Shiraki M, Hiramatsu N, Hata K, Moriya K, <u>Hino K</u> , Koike K.	Reduced Handgrip Strength Predicts Poorer Survival in Chronic Liver Diseases: A Large Multi-Center Study in Japan	Hepato Res	51	957-967	2021	
189)	Sasaki K, Nishina S, Yamauchi A, Fukuda K, Hara Y, Yamamura M, Egashira K, <u>Hino K</u> .	Nanoparticle-mediated delivery of 2-deoxy-D-glucose induces antitumor immunity and cytotoxicity in liver tumors in mice	Cell Mol Gastroenterol Hepatol	11	739-762	2021	



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
190)	Nishida N, Sugiyama M, Ohashi J, Kawai Y, Khor SS, Nishina S, Yamasaki K, Yazaki H, Okudera K, Tamori A, Eguchi Y, Sakai A, Kakisaka K, Sawai H, Tsuchiura T, Ishikawa M, <a href="#">Hino K</a> , Sumazaki R, Takikawa Y, Kanda T, Yokosuka O, Yatsuhashi H, Tokunaga K, Mizokami M.	Importance of HBsAg recognition by HLA molecules as revealed by responsiveness to different hepatitis B vaccines	Sci Rep	11	3703	2021	○
191)	Honma Y, Miyagawa K, Hara Y, Hayashi T, Kusanaga M, Ogino N, Minami S, Oe S, Ikeda M, <a href="#">Hino K</a> , Harada M.	Correlation of hepatitis C virus-mediated endoplasmic reticulum stress with autophagic flux impairment and hepatocarcinogenesis.	Med Mol Morphol	54	108-121	2021	
192)	Nishina S, Tomiyama K, Ikuta Y, Tatsumi Y, Toki A, Kato K, Yoshioka N, Sasaki K, Hara Y, <a href="#">Hino K</a> .	Long-term phlebotomy successfully alleviated hepatic iron accumulation in a ferroportin disease patient with a mutation in SLC40A1: a case report	BMC Gastroenterol	21	111	2021	
193)	Toda M, Yoshifuji A, <a href="#">Kikuchi K</a> , Komatsu M, Fujii K, Kato A, Kikuchi T, Nakazawa A, Ryuzaki M	Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients	Clin Exp Nephrol	8	1-10	2022	
194)	Sugawara Y, Iwagami M, Yoshida Y, <a href="#">Kikuchi K</a> , Ando R, Shinoda T, Ryuzaki M, Nakamoto H, Sakai K, Hanafusa N, Kashihara N, Nangaku M	Nationwide survey of the coronavirus disease 2019 prevention and treatment systems for kidney disease patients: a study of Japanese Society of Nephrology-certified educational facilities	Clin Exp Nephrol	31	1-7	2021	
195)	Sugawara Y, Iwagami M, <a href="#">Kikuchi K</a> , Yoshida Y, Ando R, Shinoda T, Ryuzaki M, Nakamoto H, Sakai K, Hanafusa N, Kashihara N, Nangaku M;	Infection prevention measures for patients undergoing hemodialysis during the COVID-19 pandemic in Japan: a nationwide questionnaire survey	Ren Replace Ther	7	27	2021	
196)	Maruyama Y, Kanda E, <a href="#">Kikuchi K</a> , Abe M, Masakane I, Yokoo T, Nitta K	Association between anemia and mortality in hemodialysis patients is modified by the presence of diabetes	J Nephrol.	34	781-790	2021	
197)	Toyoda H, <a href="#">Kikuchi K</a> , Tsuruta Y, Hiraoka A, Tsuji K, Tanaka J	Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis.	Nephrol Dial Transplant	36	1097-1103.	2021	○
198)	<a href="#">Kikuchi K</a> , Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Nakamoto H, Akizawa T	Survival and Predictive Factors in Dialysis Patients with COVID-19 in Japan: A Nationwide Cohort Stud	Ren Replace Ther	7	59	2021	
199)	Que L, Li Y, Dainichi T, Kukimoto I, Nishiyama T, Nakano Y, Shima K, Suzuki T, Sato Y, Horike S, <a href="#">Aizaki H</a> , Watashi K, Kato T, Aly HH, Watanabe N, Kabashima K, Wakae K, Muramatsu M.	Interferon-gamma induced APOBEC3B contributes to Merkel cell polyomavirus genome mutagenesis in Merkel cell carcinoma.	J Invest Dermatol.	27		2021	
200)	Kikuchi M, Sawabe M, Aoyagi H, Wakae K, Watashi K, Hattori S, Kawabe N, Yoshioka K, Tanaka J, Muramatsu M, Wakita T, <a href="#">Aizaki H</a> .	Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers.	Hepatol Int.	2	1-13	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
201)	Ishizaka A, Koga M, Mizutani T, Lim LA, Adachi E, Ikeuchi K, Ueda R, Aoyagi H, Tanaka S, Kiyono H, Matano T, <a href="#">Aizaki H</a> , Yoshio S, Mita E, Muramatsu M, Kanto T, Tsutsumi T, Yotsuyanagi H.	Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus.	Viruses.	18		2021	
202)	Fukano K, Oshima M, Tsukuda S, <a href="#">Aizaki H</a> , Ohki M, Park SY, Wakita T, Wakae K, Watashi K, Muramatsu M. NTCP oligomerization occurs downstream of the NTCP-EGFR interaction during hepatitis B virus internalization.	NTCP oligomerization occurs downstream of the NTCP-EGFR interaction during hepatitis B virus internalization.	J Virol.	6		2021	
203)	Yang Z, Ouyang T, Aoyagi H, Wang T, Xing X, Zhang Y, Wang Y, Li Y, <a href="#">Aizaki H</a> 【corresponding author】 , Li S, Kong L.	Cellular OCIAD2 protein is a proviral factor for hepatitis C virus replication.	Int J Biol Macromol.	1;188	147-159	2021	
204)	Zheng X, Guo R, Liu Q, Wakae K, Watanabe N, Fukano K, Que L, Li Y, Aly HH, Watashi K, Suzuki R, Murayama A, Kato T, <a href="#">Aizaki H</a> , Wakita T, Huang X, Yan Y, Song SJ, Muramatsu M.	Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus.	Biochem Biophys Res Commun.	11;567	1-8	2021	
205)	Takeda H, Takai A, Iguchi E, Mishima M, Arasawa S, Kumagai K, Eso Y, Shimizu T, Takahashi K, Ueda Y, Taura K, Hatano E, Iijima H, Aoyagi H, <a href="#">Aizaki H</a> , Marusawa H, Wakita T, Seno H.	Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus.	Carcinogenesis.	22		2021	
206)	Imai K, Takai K, Miwa T, Maeda T, Hanai T, Shiraki M, Suetsugu A, <a href="#">Shimizu M</a> .	Increased visceral adipose tissue and hyperinsulinemia raise the risk for recurrence of Non-B Non-C hepatocellular carcinoma after curative treatment.	Cancers	13	1542	2021	○
207)	Hanai T, Shiraki M, Nishimura K, Miwa T, Maeda T, Ogiso Y, Imai K, Suetsugu A, Takai K, <a href="#">Shimizu M</a> .	Usefulness of the stroop test in diagnosing minimal hepatic encephalopathy and predicting overt hepatic encephalopathy.	Hepato Comm	5	1518-1526	2021	○
208)	Hanai T, Hiraoka A, Shiraki M, Sugimoto R, Taniki N, Hiramatsu A, Nakamoto N, Iwasa M, Chayama, <a href="#">Shimizu M</a>	Utility of the SARC-F questionnaire for sarcopenia screening in patients with chronic liver disease: A multicenter cross-sectional study in Japan.	J Clin Med	10	3448	2021	○
209)	Hanai T, Nishimura K, Miwa T, Maeda T, Ogiso Y, Imai K, Suetsugu A, Takai K, <a href="#">Shimizu M</a>	Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.	J Gastroenterol	56	928-937	2021	○
210)	Hanai T, Shiraki M, Nishimura K, Ogiso Y, Imai K, Suetsugu A, Takai K, <a href="#">Shimizu M</a> .	Nutritional assessment tool for predicting sarcopenia in chronic liver disease.	JCSM Rapid Comm	4	150-158	2021	○
211)	Miwa T, Hanai T, Toshihide M, Ogiso Y, Imai K, Suetsugu A, Takai K, Shiraki M, Katsumura N, <a href="#">Shimizu M</a> .	Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy.	Hepato Res	51	662-673	2021	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
212)	Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, <u>Shimizu M</u> , Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.	J Gastroenterol	56	593-619	2021	○
213)	Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, <u>Shimizu M</u> , Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.	Evidence-based clinical practice guidelines for liver cirrhosis 2020.	Hepato Res	51	725-749	2021	○
214)	Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, Kanto T, Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, <u>Shimizu M</u> , Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.	J Gastroenterol	56	67-77	2021	○
215)	Takaoka Y, Miura K, Morimoto N, <u>Ikegami T</u> , Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H, Liver Investigators in the Northern Kanto Study (LINKS) group.	Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.	Hepato Res.	51(1)	51-61	2021	
216)	Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators ( <u>Ikegami T</u> )	Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.	J Gastroenterol	56(3)	261-273	2021	○
217)	榎本大、日高勲、井上泰輔、磯田広史、井出達也、荒生祥尚、内田義人、井上貴子、 <u>池上正</u> 、柿崎暁、瀬戸山博子、島上哲朗、小川浩司、末次淳、井上淳、遠藤美月、永田賢治、是永匡紹	肝疾患診療連携拠点病院における肝炎医療コーディネーターの現状	肝臓	62(2)	96-98	2021	○